Minimally invasive stabilization of pelvic metastatic bone disease: A review of an emerging technique.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 12. Curr Osteoporos Rep. 2018 Dec;16(6):703-711. doi: 10.1007/s11914-018-0490-4. Mineral and Bone Disease in Kidney Transplant Recipients. Altman AM(1), Sprague SM(2). Author information: (1)Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA. (2)Division of Nephrology and Hypertension, NorthShore University HealthSystem, University of Chicago Medical School, 2650 Ridge Avenue, Evanston, IL, 60201, USA. SSprague@northshore.org. PURPOSE OF REVIEW: Despite metabolic improvements following kidney transplantation, transplant recipients still often suffer from complex mineral and bone disease after transplantation. RECENT FINDINGS: The pathophysiology of post-transplant disease is unique, secondary to underlying pre-transplant mineral and bone disease, immunosuppression, and changing kidney function. Changes in modern immunosuppression regimens continue to alter the clinical picture. Modern management includes reducing cumulative steroid exposure and correcting the biochemical abnormalities in mineral metabolism. While bone mineral density screening appears to help predict fracture risk and anti-osteoporotic therapy appears to have a positive effect on bone mineral density, more data regarding specific treatment is necessary. Patients with mineral and bone disease after kidney transplantation require special care in order to properly manage and mitigate their mineral and bone disease. Recent changes in clinical management of transplant patients may also be changing the implications on patients' mineral and bone disease. DOI: 10.1007/s11914-018-0490-4